Endpoints News
@endpts.com
We're where the business of medicine gets answers. An independent news media organization covering biotech, pharma, science, policy, finance, venture capital and markets, and how they drive the life sciences industry. Read us at www.endpts.com.
Demis Hassabis says he's doubling down on Isomorphic amid an Alphabet and DeepMind shakeup. endpoints.news/demis-hassab...
Demis Hassabis says he's 'leaning into' Isomorphic role amid Alphabet and DeepMind shakeup
Demis Hassabis steps down as Google DeepMind CEO for an Alphabet chief scientist role and leans into AI drug startup Isomorphic; Jeff Dean exits to launch his own.
endpoints.news
Merger talks between AstraZeneca, Bristol Myers are off — report. endpoints.news/merger-talks...
Merger talks between AstraZeneca, Bristol Myers are off — report
Reuters reports AstraZeneca-Bristol Myers Squibb merger talks are off, days after Financial Times report of a $400B tie-up.
endpoints.news
Arrowhead pays $215M for a priority review voucher; Twist seeks $300M in a public offering. endpoints.news/arrowhead-bu...
Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering
Arrowhead pays $215M PRV for Redemplo; Twist targets $300M offering; Mironid raises $46M; and more.
endpoints.news
Jeremy Levin was “deeply puzzled” by the reports that AstraZeneca and Bristol Myers were considering a megadeal. Levin, chairman of Ovid Therapeutics and former executive at BMS, told Post-Hoc Live Tuesday that there's no real rationale for big companies to get bigger:
Attovia priced an upsized $289M IPO, extending biotech's first three-week listing streak since early 2025.
Attovia extends biotech IPO streak with $289M listing for three I&I drugs
Attovia Therapeutics (ATTO) raises upsized IPO on Nasdaq, extending biotech's 3-week streak. CEO Tao Fu's firm targets I&I with drugs ATTO-1310, ATTO-2306, ATTO-1091.
endpoints.news
"If you don't like setbacks and you don't like failure, don't get into the pharma industry," Novo Nordisk CEO Mike Doustdar said, as the company eyes bolt-on deals following a partial Phase 3 miss for CagriSema.
Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up
In its second-quarter results, Novo disclosed a partial miss in a Phase 3 diabetes trial of CagriSema. And it ended work on an asset that it got when it bought Inversago Pharma.
endpoints.news
Amgen cuts an early obesity candidate in a round of pipeline updates. endpoints.news/amgen-culls-...
Amgen culls early-stage obesity candidate, makes pipeline updates
Amgen drops Phase 1 obesity candidate AMG-513 after FDA partial hold. MariTide remains its obesity focus.
endpoints.news
Novo vs. Lilly: The cardiometabolic rivalry heats up in Q2. endpoints.news/novo-vs-lill...
Novo vs. Lilly: Q2's cardiometabolic grudge match
Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.
endpoints.news
Exclusive: Pathos AI is raising up to $300M at a roughly $3B valuation as it licenses an ADC from China's Alphamab and takes over an AstraZeneca cancer drug. endpoints.news/pathos-does-...
Exclusive: Pathos AI signs two deals, plans to raise Series E at $3B valuation
Pathos AI is raising up to $300M at a ~$3B valuation and inks deals for Alphamab's TROP2/HER3 ADC ($125M upfront) and AstraZeneca's oral ER degrader.
endpoints.news
🎙️ Live today at 11 a.m. ET: Jeremy Levin, former Bristol Myers dealmaker and ex-Teva CEO, joins Post-Hoc Live on the reported AstraZeneca-BMS talks — and whether pharma megamergers ever work. Join us live.
Live today at 11 am ET: Who wants an AstraZeneca-Bristol Myers megadeal?
Post-Hoc Live: ex-Teva CEO Jeremy Levin breaks down the rumored AstraZeneca–Bristol Myers megadeal in a live emergency session at 11 am ET.
endpoints.news
Pfizer is cutting another $2.5B in costs and disclosed a $4.3B write-down tied to a Seagen lung cancer drug that failed in June.
Pfizer to make $2.5B in new cost cuts
Pfizer’s yearslong cost-cutting effort is continuing apace, and it disclosed a $4.3 billion write-down tied to a Phase 3 trial miss for sigvotatug vedotin.
endpoints.news
AstraZeneca-Bristol Myers merger talk leaves Wall Street with more questions than answers. endpoints.news/biopharma-in...
AstraZeneca-Bristol Myers megamerger talk leaves Wall Street wanting more answers
The weekend report about a potential megamerger of AstraZeneca and Bristol Myers Squibb is raising a number of questions for both companies, according to biopharma analysts.
endpoints.news
FDA broadens Pluvicto's label, opening it up to most metastatic prostate cancer patients. endpoints.news/fda-expands-...
FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
It’s an important nod for Novartis, which has bet big on the radiopharmaceutical industry. The approval nearly doubles the eligible patient population for Pluvicto.
endpoints.news
As China's biotech pace accelerates, work culture becomes the new flashpoint. endpoints.news/work-ethic-b...
Work ethic becomes a flashpoint as China's biotech pace quickens
As China's biotech sector accelerates, executives at Sironax, Candid, InduPro and others weigh in on work-ethic gaps with US counterparts.
endpoints.news
AstraZeneca is in talks to merge with Bristol Myers Squibb in what would be one of pharma's largest-ever deals — sending AZ shares down 7% and BMY up nearly 7% on the news. endpoints.news/astrazeneca-...
AstraZeneca, Bristol Myers in talks about merger — report
AstraZeneca & Bristol Myers Squibb in merger talks per Financial Times. AZ worth ~$265B, BMS ~$133B. Deal may involve stock & cash; talks may not lead to deal.
endpoints.news
Supernus and Indivior are merging to form a $2.2B CNS drugmaker with 11 marketed medicines across psychiatry, neurology and addiction.
Supernus, Indivior to merge and form CNS-focused drugmaker
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
endpoints.news
Skyrizi keeps pulling away from J&J's Icotyde as AbbVie raises its full-year outlook. endpoints.news/abbvie-touts...
Skyrizi's momentum defies J&J's rival Icotyde as AbbVie raises full-year sales guidance
AbbVie's Skyrizi maintains momentum despite J&J's Icotyde competition. Q2 Skyrizi sales hit $5.5B as the company raises full-year revenue forecast.
endpoints.news
Karyopharm stock craters after Xpovio fails a second Phase 3 trial in endometrial cancer. endpoints.news/karyopharm-s...
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
Karyopharm shares crater 65% after Xpovio fails Phase 3 endometrial cancer trial; company pivots to myelofibrosis label bid.
endpoints.news
Novo Nordisk suffers a late-stage cardiovascular drug failure. endpoints.news/novo-nordisk...
Novo Nordisk rocked by late-stage cardiovascular drug failure
An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease.
endpoints.news
Apnimed raises $192M in its IPO, eyeing a 2027 sleep apnea drug launch. endpoints.news/apnimed-rais...
Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch
Apnimed raised IPO funds on Nasdaq ($APMD) to launch OSA pill AD109/Oxnimbi in 2027, with FDA decision due Feb. 28, 2027. CEO Kevin Lind leads revamped team.
endpoints.news
Ionis' chief scientist Frank Bennett retires; Recursion names its first AI chief. endpoints.news/ionis-top-sc...
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
Bennett will retire in February 2027 after starting at Ionis as a founding scientist in 1989.
endpoints.news
Trump's 100% pharma tariffs were set to kick in Friday — but all 17 targeted drugmakers cut MFN deals with the administration, leaving no one left to tax. endpoints.news/first-round-...
Trump's pharma tariffs won't kick in Friday because there's no one left to kick
First round of Trump's 100% pharma tariffs was set for July 31 but they're not being imposed because the 17 companies have MFN and onshoring deals.
endpoints.news
New Sanofi CEO Garijo lays out her plan: R&D cleanup, more M&A and a China push. endpoints.news/garijos-plan...
Garijo's plan to revamp Sanofi: an R&D cleanup, more M&A and a China push
Sanofi CEO Garijo details turnaround plan — R&D pipeline cleanup, bigger M&A, deeper China push — as stock falls 9% amid looming Dupixent patent cliff.
endpoints.news
Takeda, Regeneron, Sanofi and Bristol Myers all cut programs in a wave of pipeline trims. endpoints.news/takeda-regen...
Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines
Takeda, Regeneron, Sanofi and BMS trim pipelines in Q2 updates; BMS drops Ph3 prostate cancer degrader BMS-986365, Takeda cuts celiac drug TAK-101.
endpoints.news
Relation promises 'transformationally different success rates' in expanded AI pact with GSK. endpoints.news/relation-pro...
Relation promises 'transformationally different success rates' in expanded AI pact with GSK
Relation expands its GSK partnership for up to $110M, tapping new AI model MORGAN to sharpen drug discovery and biology insights.
endpoints.news
Sanofi takes a €1B+ write-off and drops two immunology programs. endpoints.news/sanofi-recor...
Sanofi records €1B+ write-off, ends work on two immunology assets
Sanofi books over €1B in Q2 impairment charges axing amlitelimab, balinatunfib and itepekimab, and upgrades 2026 sales guidance to ~10% growth.
endpoints.news
FTC sues Hims over sensitive health data sharing and billing practices. endpoints.news/ftc-sues-him...
FTC sues Hims for sharing sensitive health information, billing practices
FTC sued Hims & Hers for sharing health data with Meta and Snap, and deceptive billing. Hims denies claims; shares dropped more than 10%.
endpoints.news
Atea's hep C pill matches Gilead's in new data; AbCellera closes its second deal in two months. endpoints.news/ateas-hep-c-...
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for schizophrenia drug.
endpoints.news
Two biotechs turn to reverse mergers to advance an I&I drug and a BTK inhibitor. endpoints.news/two-biotechs...
Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK inhibitor.
endpoints.news
Leqembi posts its strongest quarter yet as Biogen raises guidance. endpoints.news/leqembi-reco...
Leqembi records best quarter since launch as Biogen raises underlying guidance
Leqembi posts record $184M in Q2, its third straight quarter of growth, as Biogen lifts full-year guidance and folds in Apellis.
endpoints.news